NMPA zolbetuximab coverage for business development, investment, and market access teams
The Phase 2 trial of zolbetuximab combined with mFOLFOX6 and nivolumab shows promising results for treating unresectable CLDN18.2-positive gastric cancer. This breakthrough could reshape treatment protocols and investment strategies in oncology.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
